Our Analysis·June 1, 2026·13 min read

What Invisix’s €20M Seed Signals for Semiconductor Metrology

A €20M Seed for an ASML-origin soft-X-ray metrology spinout is a serious productization signal in a category where advanced chipmakers are running out of visibility inside 3D structures.

Context

Today, Invisix announced a €20M Seed round to bring soft-X-ray metrology to AI-era chip manufacturing. The company is a 2025-founded ASML-origin spinout using broadband high-harmonic-generation soft X-rays, reconstruction algorithms and machine learning to measure internal 3D semiconductor structures without cutting wafers open. The money is meant to grow the team, accelerate a first shippable system and support customer demonstrations from a new Eindhoven cleanroom with a 300mm-wafer-capable testbench.

The thesis is very specific: leading-edge chipmakers are not just short of compute capacity, they are short of measurement capacity. GAA, nanosheet, CFET, advanced DRAM, 3D NAND and advanced packaging all make the same problem worse. More critical structures are buried, stacked, thinner and harder to measure with visible-light tools. Yield becomes a measurement problem as much as a process problem.

That is why this Seed is more interesting than the round size alone. Invisix is not a normal early lab spinout trying to prove the physics from scratch. The core soft-X-ray technology was developed for more than a decade inside ASML, licensed into Invisix and publicly demonstrated in 2023 with Intel and imec on gate-all-around transistor features. That lowers technology-origin risk, but it does not remove the hard part: turning a research-grade stack into a fab-relevant system with throughput, uptime, repeatability, recipes, serviceability and process-control integration.

The tension is simple. Invisix just raised one of the largest visible Seed rounds in its narrow category, but it is entering a market where Nearfield has already raised €135M, Rigaku and Bruker have public-company balance sheets, and fabs will not adopt a new metrology tool because the physics is elegant. They will adopt it only if it solves painful, high-value inspection problems better than existing optical, e-beam, X-ray and hybrid metrology stacks.

Q1What does Invisix’s €20M Seed signal versus direct competitors?

Invisix’s €20M Seed is large for a Seed-stage entrant, but it does not make the company the best-funded player in its direct competitive set.

Among direct competitors, Invisix is not the largest recent financing. Rigaku raised about $863M in its October 2024 IPO. Bruker priced a $600M mandatory convertible preferred stock offering in September 2025. Nearfield Instruments raised €135M, about $148M, in a July 2024 Series C. Invisix’s €20M Seed is larger than Sigray’s latest visible small or grant-style disclosed funding, but it is far below the mature public-company raises and Nearfield’s late-stage private round.

The cleanest benchmark is Nearfield.

Nearfield is the relevant private benchmark because it also targets inline or near-inline, non-destructive process-control metrology for advanced 3D semiconductor structures. Nearfield’s last round was roughly 6.7x larger than Invisix’s Seed, using €135M versus €20M.

That gap is meaningful, but it should not be read as negative. Nearfield is older, founded in 2016, and had reached a later Series C scale-up phase. Invisix is a 2025-founded ASML-origin spinout moving into productization.

The best read is that Invisix is now credible, but not capital-dominant. The Seed gets it into the serious private-company set, while Nearfield remains the clearest funding leader among private metrology challengers.

We go deeper on this point in our latest market report.

Methodology note Direct-competitor comparisons separate public-company capital events from private-company venture rounds. Rigaku and Bruker are included for operating context, while Nearfield is treated as the cleanest private-company benchmark. See full methodology below.

Q2How unusual is Invisix’s Seed compared with Seed-stage peers?

Invisix’s €20M Seed looks unusually large versus visible Seed-stage and adjacent early-stage benchmarks.

The same-stage benchmark set is much smaller than Nearfield.

Depending on the exact peer set, Invisix’s low-$20M equivalent Seed is roughly 3x to 6x larger than visible disclosed Seed benchmarks. That is the strongest positive size signal.

The round size also fits the commercialization challenge. Invisix is not funding a software MVP. It is funding a hard systems path: team growth, a first shippable system, customer demonstrations, cleanroom work, 300mm-wafer-capable testing, algorithms, applications, supply chain, and initial commercial leadership.

A €20M Seed looks expensive in normal startup terms. For a semiconductor equipment company trying to industrialize ASML-origin soft-X-ray technology, it looks reasonable.

The strongest conclusion is that Invisix raised a Seed sized for serious productization, not just research validation.

Methodology note Same-stage comparisons use visible disclosed Seed or adjacent early-stage rounds where the company is tied to metrology, inspection, advanced sensing or non-invasive imaging. The benchmark is directional because some peers are only adjacent to semiconductor process control. See full methodology below.

Q3Is Invisix’s Seed the largest recent category round?

Invisix appears to be the largest recent disclosed round in advanced semiconductor process-control metrology and inspection equipment, but not the largest round in the broader recent category window.

The recent category ranking depends on the time window.

Within advanced semiconductor process-control metrology and inspection equipment, the last 12 months include Invisix’s €20M Seed and EuQlid’s $3M round. Invisix is therefore the #1 recent disclosed round in the category over that period.

That is a stronger positive signal than the direct-competitor ranking. Invisix is not outspending Nearfield, Rigaku, or Bruker, but it is attracting the largest recent capital allocation among emerging companies in the category.

Over the last 24 months, Invisix appears to be the #2 disclosed funding recipient in the category, behind Nearfield. Nearfield captured roughly 78% of disclosed 24-month category capital. Invisix captured roughly 11% to 12%.

The most important size signal is therefore not “largest ever.” It is “large enough to signal serious productization intent.” Invisix has raised a Seed that looks scaled for cleanroom demos and first-system engineering, not just research.

Methodology note Category leadership is measured over 12-month and 24-month announcement windows, using disclosed funding amounts in the retained advanced semiconductor process-control metrology and inspection equipment set. See full methodology below.

Q4How well-funded is Invisix today compared with its competitors?

Invisix is meaningfully funded for a Seed-stage entrant, but it remains far less funded than Nearfield Instruments, Rigaku, and Bruker.

The useful ranking depends on the comparison type.

Invisix’s cumulative disclosed funding is €20M, or roughly low-$20M in USD terms. That places it above Sigray’s clearly disclosed funding, but below Nearfield’s approximately $169M total disclosed funding and far below the recent public-market capital raises of Rigaku and Bruker.

The clean private-company comparison is Nearfield. Nearfield has raised roughly 7x to 8x more cumulative disclosed funding than Invisix, depending on currency conversion. That is a large gap, but it mostly reflects maturity. Nearfield is a Series C company with more time to raise capital, build systems, and prove deployment.

Before the Seed, Invisix had no clean public cumulative funding amount. Samsung was reportedly involved in late 2025 and took a minority stake, but the amount and relationship to the €20M Seed are not publicly clear. Before the Seed, Invisix was probably last or tied-last among direct competitors by disclosed funding. After the Seed, it moves ahead of Sigray on disclosed funding, but remains behind Nearfield, Bruker, and Rigaku.

Invisix looks fast-funded, but the metric should be read carefully. Founded in 2025 and already at €20M disclosed funding by June 2026, Invisix has raised roughly low-$20M per year on a simple annualized basis. Nearfield, founded in 2016 with roughly $169M disclosed funding by 2026, has averaged around $16M per year.

That does not mean Invisix is more successful than Nearfield. The denominator is very short, and one large Seed can distort the result. The better interpretation is that Invisix was able to raise institutional-scale capital unusually early because its technology was pre-incubated inside ASML.

Funding acceleration cannot be measured cleanly. There is no previous disclosed priced round amount. The Samsung-related late-2025 reporting is strategically important, but it does not provide a usable amount, stage, or confirmed relationship to the €20M Seed.

Funding relative to headcount should also be skipped quantitatively. The company website shows open roles, including software, supply chain, commercial leadership, applications, and project leadership positions. That hiring mix is informative, but open roles are not headcount.

The better qualitative read is that Invisix is hiring for the transition from research validation to customer demos and first-product industrialization. That fits the size and purpose of the Seed.

The conclusion is clear: Invisix is well-funded for a Seed company, underfunded versus scaled competitors, and unusually fast-funded because of ASML-origin technology. The €20M Seed gives Invisix credibility and runway to prove industrial relevance. It does not yet give the company enough capital to out-execute the established metrology ecosystem.

Methodology note Cumulative funding comparisons include only disclosed amounts. The Samsung-related investment signal is treated qualitatively because the amount, round name and relationship to the Seed were not confirmed in the supplied source set. See full methodology below.

Q5How active is funding in advanced semiconductor process-control metrology?

Funding activity is selective and narrow, with only a few disclosed companies raising over the last 24 months.

The category includes companies building inline or near-inline tools that measure critical dimensions, 3D profiles, buried structures, overlay, defects, thin films, process variation, and hard-to-see features in advanced logic, memory, packaging, and 3D semiconductor structures.

It excludes generic microscopy, broad industrial inspection without semiconductor process-control focus, pure EDA, finished-chip electrical test, and general wafer-processing tools that do not primarily measure or inspect.

Recent disclosed activity is limited.

Over the last 6 months, only 1 disclosed-amount company raised in this category: Invisix. Over the last 12 months, 2 disclosed-amount companies raised: Invisix and EuQlid. Over the last 24 months, 5 disclosed-amount companies raised: Nearfield Instruments, QuantumDiamonds, Wooptix, EuQlid, and Invisix.

Additional activity exists around FemtoMetrix and Sigray, but those signals are harder to include in clean funding totals because amounts, round types, or comparability are unclear.

Capital raised in the category was roughly $22M over the last 6 months, roughly $25M over the last 12 months, and roughly $190M over the last 24 months, using approximate USD equivalents. The 24-month number is dominated by Nearfield’s €135M Series C, or about $148M.

Invisix’s low-$20M equivalent Seed is the largest disclosed category round over the last 12 months. Nearfield remains the dominant 24-month funding event.

Deal count is not accelerating. The last 6 months had 1 disclosed deal, Invisix, while the previous 6 months also had 1 disclosed deal, EuQlid. The last 12 months had 2 disclosed deals, Invisix and EuQlid, while the previous 12 months had 3 disclosed deals, Nearfield, Wooptix, and QuantumDiamonds.

Capital deployment gives a mixed signal. Over the last 6 months, category capital was roughly $22M, compared with roughly $3M in the previous 6 months, meaning near-term deployment accelerated because Invisix’s Seed was much larger than EuQlid’s round. But over the last 12 months, category capital was roughly $25M, compared with roughly $165M in the previous 12 months, meaning capital deployment decelerated sharply versus the Nearfield-heavy prior period.

The right interpretation is that the category is not broadly accelerating in a smooth, linear way. It is selective and event-driven.

It’s actually something we elaborate on in our latest market report.

Methodology note Market-activity analysis uses announcement-date windows and disclosed-amount rounds only. FemtoMetrix and Sigray are discussed qualitatively where relevant, but excluded from clean activity totals when amount, round type or comparability is unclear. See full methodology below.

Q6How concentrated is funding in the category?

Funding is extremely concentrated, with Nearfield and Invisix capturing most disclosed capital in the recent category window.

The 24-month capital split is dominated by Nearfield.

Nearfield captured roughly 78% of disclosed 24-month category capital. Invisix captured roughly 11% to 12%. Wooptix captured around 5% to 6%, QuantumDiamonds around 4%, and EuQlid around 2%.

The top three companies, Nearfield, Invisix, and Wooptix, captured roughly 95% of disclosed 24-month category capital. That is not a broad venture wave. It is a narrow funding market where investors are placing relatively few high-conviction bets on companies with strong technical credibility, strategic customer relevance, or differentiated physics.

This pattern is normal for semiconductor equipment. One large round can dominate a two-year period because the number of credible startups is small and the technical bar is extremely high.

The strongest category signal is that Invisix is the largest recent round, but not the largest category round. Invisix is not yet the capital leader. Nearfield is. But Invisix is the clearest new funding signal that investors still believe advanced semiconductor metrology remains open for new entrants, especially when the startup has ASML-origin technology, strategic investors, and a path toward customer demos.

Methodology note Capital concentration is calculated by summing disclosed category rounds over the 24-month window and dividing each company’s retained round amount by the total. Shares are approximate because currency conversion and “over” round language create small ranges. See full methodology below.

Q7How strong is the thesis behind Invisix’s Seed?

The thesis is strong because several companies have recently raised around a similar idea: advanced semiconductor manufacturing needs better non-destructive, inline, and 3D process-control metrology.

The similar-thesis set includes Invisix, Nearfield Instruments, Wooptix, and EuQlid. These companies are not identical in physics or go-to-market stage, but they share the same strategic premise: advanced chips are becoming too complex, three-dimensional, buried, and yield-sensitive for legacy inspection alone.

The similar-thesis funding pattern is visible.

That is not a crowded market, but it is enough to show a real pattern. Invisix is not a one-off financing built on a lonely thesis.

The capital totals are meaningful. Similar-thesis companies raised roughly €20M over the last 6 months, roughly €22.8M over the last 12 months, and roughly €167.8M over the last 24 months, using approximate euro equivalents. The 24-month total is dominated by Nearfield’s €135M Series C. Without Nearfield, the thesis set still raised roughly €32.8M across Invisix, Wooptix, and EuQlid.

Invisix is the #2 recent thesis-set funding recipient.

Nearfield is the closest thesis comparable. It raised €135M in a Series C announced on July 18, 2024, about 22.5 months before Invisix’s announcement. Nearfield sells inline, non-destructive process-control nanometrology for advanced 3D memory and logic.

Its technical approach differs from Invisix, but the commercial problem is almost the same: advanced 3D chips require better process-control metrology to protect yield.

Wooptix is the second close semiconductor metrology comparable. It raised over €10M in a Series C announced in early 2025, about 15 months before Invisix. Its thesis is semiconductor metrology using wavefront phase imaging to improve process insight. It is similar because Samsung Venture Investment led the round and the company is framed around semiconductor metrology for advanced manufacturing.

Wooptix is less similar than Nearfield because public materials do not show the same explicit soft-X-ray or buried 3D GAA profile focus.

EuQlid is adjacent-close. It emerged from stealth on November 4, 2025, about 7 months before Invisix, with $3M raised and more than $1.5M in early customer revenue. Its thesis is quantum-sensing-based, non-invasive 3D imaging of semiconductors and batteries.

The similarity is strong at the problem level: manufacturers need to see internal structures and current paths without destructive inspection. The modality and stage differ, but the investor logic is similar.

Adjacent-sector examples support the broader pattern, but should not be treated as direct comps. SirenOpt raised $6.5M in October 2025 for real-time, non-destructive process-control inspection in battery and advanced manufacturing. Lumafield raised a $75M Series C in March 2025 for industrial X-ray CT technology that helps manufacturers see inside complex products.

These are not semiconductor process-control metrology peers. They support the broader idea that internal visibility is becoming strategically important in complex physical manufacturing.

If you want to understand why these investors decided to bet on this, get our latest market report.

Methodology note The similar-thesis set retains companies whose round narrative is more than 80% aligned with Invisix’s thesis at the problem level: non-destructive, inline or near-inline measurement of buried or complex physical structures. Adjacent-sector examples are used for thesis context, not direct competition. See full methodology below.

Q8What real-world signals support the Invisix thesis?

The real-world evidence is strong because advanced semiconductor manufacturing is becoming more 3D, more buried, and harder to measure without damaging structures.

TSMC’s N2 process entered volume production in Q4 2025, making GAA and nanosheet manufacturing a current production reality rather than only a roadmap topic. That matters because GAA, nanosheet, forksheet, CFET, HBM, and advanced packaging all increase the need for better internal visibility and tighter process control.

Rigaku and imec announced next-generation X-ray semiconductor metrology work in May 2026, specifically tied to GAA, CFET, memory density, and non-destructive measurement for stable mass production. Nearfield also signed a multi-year metrology development project in November 2025. These signals support the view that fabs and ecosystem players are actively looking for better non-destructive measurement methods.

The thesis is not risk-free. TSMC appears to be ramping N2 without a visible dependency on soft-X-ray tools, which shows leading fabs are not helpless. AI-enhanced optical metrology is still advancing. Applied Materials launched faster e-beam tools for buried nanoscale structures. X-ray methods may also face throughput and recipe-development challenges.

So Invisix does not need to replace the full metrology stack. It needs to win specific high-value use cases where soft-X-ray measurement is clearly better than existing alternatives.

The strongest read is that the market pain is real, but adoption will be demanding. Fabs will only adopt Invisix if the tool proves throughput, uptime, repeatability, recipe usability, data interpretability, and integration into production workflows.

Methodology note Real-world support is based on manufacturing inflection signals, ecosystem activity and tool-development announcements, not on confirmed Invisix revenue or customer contracts. Adoption risk is kept separate from thesis strength. See full methodology below.

Q9What is the final funding read on Invisix?

Invisix’s €20M Seed is a strong productization signal, not a category-dominating funding event.

The round is unusually large for a Seed-stage semiconductor metrology startup and appears to be the largest recent disclosed round in its category. It also makes Invisix one of the few emerging companies attracting meaningful capital in advanced semiconductor process-control metrology.

But Invisix is not yet the capital leader. Nearfield remains the strongest private-company benchmark, with a much larger funding base and a later commercialization stage. Rigaku and Bruker are important operating competitors, but their public-company capital events are not clean venture comps.

The funding signal is therefore strong but specific. Invisix has enough capital to pursue credible cleanroom demonstrations, first-system engineering, customer validation, and early commercialization. It does not yet have enough capital to prove full fab-scale adoption or out-execute the established metrology ecosystem.

The next major signal will be whether Invisix can convert this Seed into technical proof, customer traction, and a much larger Series A or Series B.

Methodology note The final read combines Seed-stage scale, private-company comparables, category concentration and use-of-funds evidence. It does not treat public-company financing events as equivalent to startup funding rounds. See full methodology below.

In our semiconductor industry deck, you will find everything you need to understand the market

§

Methodology, Sources & Disclosure

All timing comparisons in this note are measured as of June 1, 2026. Funding-round time windows refer to announcement dates, not legal close dates, unless a close date is separately disclosed. Because the legal close date for Invisix’s Seed was not found in the supplied source set, June 1, 2026 is treated as the public announcement date.

The retained investment thesis behind Invisix’s €20M Seed is that advanced chipmakers are losing visibility inside the 3D structures they now need to manufacture, and that inline, non-destructive, high-throughput metrology becomes a strategic bottleneck as GAA, nanosheet, CFET, advanced DRAM, 3D NAND and advanced packaging structures get harder to inspect. This thesis was retained because Invisix’s round was framed around soft-X-ray metrology, AI-era chip manufacturing, customer demonstrations, a 300mm-wafer-capable testbench and a first shippable system.

The category used for market-activity analysis is advanced semiconductor process-control metrology and inspection equipment. It includes companies building inline or near-inline tools that measure critical dimensions, overlay, 3D profiles, buried structures, thin films, defects, stress, composition or process variation in semiconductor manufacturing, especially for advanced logic, DRAM, 3D NAND, advanced packaging and future CFET / GAA devices. It excludes generic academic microscopy, pure EDA, wafer-processing tools that primarily change the wafer rather than measure it, finished-chip electrical test, and generic industrial inspection tools without semiconductor process-control focus.

The direct competitor set used for funding comparisons includes Nearfield Instruments, Rigaku, Bruker and Sigray. Nearfield is the cleanest private-company benchmark because it targets inline, non-destructive process-control metrology for advanced 3D logic and memory. Rigaku and Bruker are included for operating competition, but their IPO and preferred-stock financing events are public-company capital events, not clean venture-stage comps. KLA, Nova, Onto Innovation, ASML YieldStar, FemtoMetrix and Wooptix were not treated as direct competitors in the narrow comparison because the supplied evidence did not show enough head-on overlap with Invisix’s specific soft-X-ray / buried-3D-profile use case. Competitor funding rankings include only private or venture-backed companies with comparable disclosed financing data.

Funding activity counts include disclosed-amount rounds in the retained category over 6-month, 12-month and 24-month windows. The retained 24-month category activity set is Nearfield Instruments, QuantumDiamonds, Wooptix, EuQlid and Invisix. FemtoMetrix and Sigray are discussed qualitatively where relevant, but not included in clean category totals when the amount, round type or comparability is unclear.

The similar-thesis set includes companies whose round narrative is more than 80% aligned with Invisix’s retained thesis at the problem level: non-destructive, inline or near-inline measurement of buried, internal or complex physical structures. The retained peer rounds are Nearfield Instruments’ €135M Series C, Wooptix’s over €10M Series C, EuQlid’s $3M stealth emergence / funding disclosure and Invisix’s €20M Seed. SirenOpt and Lumafield are used only as adjacent-sector context because their narratives support the broader “see inside complex products without destroying them” thesis, but they are not semiconductor process-control metrology peers.

Category capital concentration is calculated by summing disclosed funding rounds in the retained category set over the relevant period. When round amounts are disclosed as “over” or “about” a given figure, concentration figures are treated as approximate and use the disclosed lower bound or the supplied approximate conversion. Currency conversions are directional and used only to compare order of magnitude across euro, dollar and pound disclosures.

We selected these sources because they come either from direct company announcements, company-controlled pages, authoritative semiconductor ecosystem sources, or funding / industry publications that provide independent validation and comparable market signals: Invisix company website, Invisix publications page, Invisix careers page, Business Wire syndicated Invisix Seed announcement, The Next Web coverage of Invisix’s Seed, High-Tech Systems Magazine coverage of Invisix’s ASML spinout context, KED Global coverage of Samsung’s Invisix investment, Benzinga coverage of Samsung’s Invisix investment, Nearfield Instruments €135M Series C announcement, Wooptix Series C announcement, EEJournal coverage of EuQlid’s stealth emergence, Tech Funding News coverage of SirenOpt’s $6.5M round, Lumafield $75M Series C announcement, SPIE Digital Library review on X-ray metrology for advanced semiconductor manufacturing, NIST CHIPS R&D Metrology Program, CB Insights profile of Invisix.

We are not affiliated with Invisix, its investors, or the named comparable companies. No payment, consideration, or commitment of future business has been received from Invisix, its investors, or any named comparable company in connection with this note. Nothing herein constitutes investment advice or an offer to transact in any security.